Page 2,803«..1020..2,8022,8032,8042,805..2,8102,820..»

Battle with GOP lawmakers over stem cells could cost U-M state aid

Posted: March 27, 2012 at 7:45 pm

A battle is heating up between a Republican-led state House panel and the University of Michigan over whether U-M must disclose its number of embryonic stem-cell lines.

It's the latest in a series of disagreements in recent months about everything from university funding to unionization of graduate student research assistants.

This time, Republicans on the subcommittee are upset with what they call U-M's "thumbing of their nose" at requests for information about embryonic stem cells. Several lawmakers said that if they don't get the information -- required under language passed in last year's budget -- they'll look at docking U-M's state aid.

U-M President Mary Sue Coleman said the university doesn't have an exact number of stem cells. She said it's important, instead, to place the work in the context of medical advances stem cells are leading.

Leonard Fleck, an ethics professor at Michigan State University's Center for Ethics and Humanities in the Life Sciences, said he doesn't believe lawmakers should legislate with the budget. He said that will be especially true as a better understanding of human genetics transforms medicine but runs afoul of some religious convictions.

Rep. Kevin Cotter, R-Mt. Pleasant, admitted the issue is about more than stem-cell research.

"It about the power of the Legislature to ask for reports. We're going to stand behind those requirements," he said.

Those involved in stem-cell research say a feud between Republican members of the state House higher education subcommittee and the University of Michigan is more about personal beliefs than state mandates.

The subcommittee is demanding to know the number of embryonic stem-cell lines and four related numbers at U-M. In a private meeting earlier this year, the chairman of the subcommittee told U-M officials they could lose state funding if they don't give those details.

U-M didn't give legislators the numbers, and now several committee members say they want to dock some of its state aid for flaunting the Legislature.

Follow this link:
Battle with GOP lawmakers over stem cells could cost U-M state aid

Posted in Stem Cell Videos | Comments Off on Battle with GOP lawmakers over stem cells could cost U-M state aid

Midlands Vet Uses Stem Cell Therapy for Pets in Pain

Posted: March 27, 2012 at 7:45 pm

Columbia, SC (WLTX) --What if your pet couldn't walk anymore? One Midlands vet is using stem cell therapy to help.

For Beth Phibbs it's almost like a turning back of the hands of time.

"I call her my little miracle dog, because she's doing things she used to do," said Phibbs. "Now she's not on any medication, and she can go up and down the steps and she runs and jumps and things that she used to do when she was five."

Phibbs has spent the last 13 years loving and looking after her pet dog Maggie, and when she pet began to develop arthritis and a limp she had to take action. But when the first treatments stopped working, Phibbs and Maggie had to look to another options, dog stem cell therapy.

"I had no idea that animals were able to have they type of procedures," she said.

Dr. Kenneth Banks a veterinarian with the Bank Animal Hospital, performed the surgery for Maggie using her own stem cells in the one day procedure.

Banks said the stem cell therapy not only cost less than some other options, but was less invasive and had a quicker recovery time as well.

Still with about three similar procedures under his belt, even he didn't expect to see a such change in maggie just 40 days after the surgery.

"I wasn't sure we were gonna get the results this fast, we were expecting results, maybe not a good as she's done. We're real happy with her results," said Banks.

Now, after three years on medication and walking with a limp, Maggie's getting used to a new way of life -- one with out pain in her golden years.

Go here to read the rest:
Midlands Vet Uses Stem Cell Therapy for Pets in Pain

Posted in Stem Cell Treatments | Comments Off on Midlands Vet Uses Stem Cell Therapy for Pets in Pain

Cell Therapy Improves Damaged Heart In Study

Posted: March 27, 2012 at 7:44 pm

March 27, 2012

According to a new study, using a patients own bone marrow may help repair damaged areas of the heart caused by heart failure.

Researchers found that left ventricular ejection fraction increased by 2.7 percent in patients who received stem cell therapy.

The study, which was presented at the American College of Cardiologys 61st Annual Scientific Session, revealed that the improvement in ejection fraction correlated with the number of CD34+ and CD133+ cells in the bone marrow.

This is the kind of information we need in order to move forward with the clinical use of stem cell therapy, Emerson Perin, MD, PhD, director of clinical research for cardiovascular medicine at the Texas Heart Institute and the studys lead investigator, said at the event.

The study included 92 patients who were randomly selected to receive stem cell treatment or placebo. The patients all had chronic ischemic heart disease and an ejection fraction of less than 45 percent along with heart failure.

Doctors placed a catheter in the hearts left ventricle to inject 3 ccs, or 100 million stem cells, into an average of 15 sites of the stem cell patients hearts.

The doctors used electromechanical mapping of the heart to measure the voltage in areas of the heart muscle and create a real-time image of the heart.

With this mapping procedure, we have a roadmap to the heart muscle, said Dr. Perin. Were very careful about where we inject the cells; electromechanical mapping allows us to target the cell injections to viable areas of the heart.

The trial was designed to determine whether left ventricular end systolic volume and myocardial oxygen consumption improved in patients who received stem cell treatment.

Follow this link:
Cell Therapy Improves Damaged Heart In Study

Posted in Stem Cell Research | Comments Off on Cell Therapy Improves Damaged Heart In Study

Stem cell study aids quest for motor neurone disease therapies

Posted: March 27, 2012 at 7:44 pm

Public release date: 26-Mar-2012 [ | E-mail | Share ]

Contact: Tara Womersley tara.womersley@ed.ac.uk 44-131-650-9836 University of Edinburgh

A breakthrough using cutting-edge stem cell research could speed up the discovery of new treatments for motor neurone disease (MND).

The international research team has created motor neurones using skin cells from a patient with an inherited form of MND.

The study discovered that abnormalities of a protein called TDP-43, implicated in more than 90 per cent of cases of MND, resulted in the death of motor neurone cells.

This is the first time that scientists have been able to see the direct effect of abnormal TDP-43 on human motor neurons.

The study, led by the University of Edinburgh's Euan MacDonald Centre for Motor Neurone Disease Research, was carried out in partnership with King's College London, Colombia University, New York and the University of San Francisco.

MND is a devastating, untreatable and ultimately fatal condition that results from progressive loss of the motor nerves motor neurones that control movement, speech and breathing.

Professor Siddharthan Chandran, of the University of Edinburgh, said: "Using patient stem cells to model MND in a dish offers untold possibilities for how we study the cause of this terrible disease as well as accelerating drug discovery by providing a cost-effective way to test many thousands of potential treatments."

The study, funded by the MND Association, is published in the journal PNAS

See the rest here:
Stem cell study aids quest for motor neurone disease therapies

Posted in Stem Cell Research | Comments Off on Stem cell study aids quest for motor neurone disease therapies

Houston study shows stem-cell's potential for heart treatment

Posted: March 27, 2012 at 7:44 pm

Houston researchers are reporting that adult stem cells have a modest benefit in younger patients with heart failure, the first large-scale evidence that the controversial yet promising new therapy can be developed to help millions of people with the disease.

In a study presented at a cardiology conference Saturday, Texas Heart Institute doctors presented results of a clinical trial showing that cells derived from patients' own bone marrow produce a small but significant increase in the heart's ability to pump oxygen-rich blood.

"This study moves us one step closer to being able to help patients with severe heart failure who lack other alternatives," said Dr. James Willerson, president of the Texas Heart Institute and the study's principal investigator. "It also points to a future in which stem cells regenerate the heart."

The study did not find improvements in a number of heart function measures, but Willerson and other study leaders said it yielded key information about the specific adult stem cells with the greatest therapeutic potential. The trial used a number of stem cell types.

Transplants limited

About 6 million people in the United States have heart failure, a progressive and eventually fatal disease in which the heart loses the ability to effectively pump sufficient amounts of blood to the body's organs. Better therapy is needed because the limited availability of donor hearts makes transplants an option for only about 2,300 people in the United States annually.

Adult stem cells have become the subject of studies for a variety of conditions - the Texas Heart Institute has many involving the heart - since laboratory research in the late 1990s showed they have the ability to grow into most any kind of tissue. This is the first intermediate-stage study in the United States, characterized by multiple centers and many dozens of patients.

The idea of therapy involving adult stem cells formerly was considered non-controversial, a more ethical alternative to destroying embryos to obtain their stem cells. But it has come under fire recently because it is increasingly being used outside of research studies and for profit, particularly in Texas, where Gov. Rick Perry received it last year for his ailing back. The unregulated activity has prompted complaints to the U.S. Food and Drug Administration and a Texas Medical Board draft policy requiring oversight for any use of experimental drugs.

3.1 percent increase

The new study, presented at an American College of Cardiology conference and to be published in the Journal of the American Medical Association, involved 92 patients at five locations - two-thirds at the Texas Heart Institute - whose hearts were pumping at less than 45 percent of capacity and could not be treated with surgery. Doctors injected patients' own stem cells or placebos into their hearts.

View original post here:
Houston study shows stem-cell's potential for heart treatment

Posted in Stem Cell Research | Comments Off on Houston study shows stem-cell's potential for heart treatment

Cell Therapy Improves Damaged Heart In Study

Posted: March 27, 2012 at 3:10 pm

March 27, 2012

According to a new study, using a patients own bone marrow may help repair damaged areas of the heart caused by heart failure.

Researchers found that left ventricular ejection fraction increased by 2.7 percent in patients who received stem cell therapy.

The study, which was presented at the American College of Cardiologys 61st Annual Scientific Session, revealed that the improvement in ejection fraction correlated with the number of CD34+ and CD133+ cells in the bone marrow.

This is the kind of information we need in order to move forward with the clinical use of stem cell therapy, Emerson Perin, MD, PhD, director of clinical research for cardiovascular medicine at the Texas Heart Institute and the studys lead investigator, said at the event.

The study included 92 patients who were randomly selected to receive stem cell treatment or placebo. The patients all had chronic ischemic heart disease and an ejection fraction of less than 45 percent along with heart failure.

Doctors placed a catheter in the hearts left ventricle to inject 3 ccs, or 100 million stem cells, into an average of 15 sites of the stem cell patients hearts.

The doctors used electromechanical mapping of the heart to measure the voltage in areas of the heart muscle and create a real-time image of the heart.

With this mapping procedure, we have a roadmap to the heart muscle, said Dr. Perin. Were very careful about where we inject the cells; electromechanical mapping allows us to target the cell injections to viable areas of the heart.

The trial was designed to determine whether left ventricular end systolic volume and myocardial oxygen consumption improved in patients who received stem cell treatment.

Here is the original post:
Cell Therapy Improves Damaged Heart In Study

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Cell Therapy Improves Damaged Heart In Study

Cell Therapy Improves Damaged Heart In Study

Posted: March 27, 2012 at 2:31 pm

March 27, 2012

According to a new study, using a patients own bone marrow may help repair damaged areas of the heart caused by heart failure.

Researchers found that left ventricular ejection fraction increased by 2.7 percent in patients who received stem cell therapy.

The study, which was presented at the American College of Cardiologys 61st Annual Scientific Session, revealed that the improvement in ejection fraction correlated with the number of CD34+ and CD133+ cells in the bone marrow.

This is the kind of information we need in order to move forward with the clinical use of stem cell therapy, Emerson Perin, MD, PhD, director of clinical research for cardiovascular medicine at the Texas Heart Institute and the studys lead investigator, said at the event.

The study included 92 patients who were randomly selected to receive stem cell treatment or placebo. The patients all had chronic ischemic heart disease and an ejection fraction of less than 45 percent along with heart failure.

Doctors placed a catheter in the hearts left ventricle to inject 3 ccs, or 100 million stem cells, into an average of 15 sites of the stem cell patients hearts.

The doctors used electromechanical mapping of the heart to measure the voltage in areas of the heart muscle and create a real-time image of the heart.

With this mapping procedure, we have a roadmap to the heart muscle, said Dr. Perin. Were very careful about where we inject the cells; electromechanical mapping allows us to target the cell injections to viable areas of the heart.

The trial was designed to determine whether left ventricular end systolic volume and myocardial oxygen consumption improved in patients who received stem cell treatment.

See original here:
Cell Therapy Improves Damaged Heart In Study

Posted in Stem Cell Therapy | Comments Off on Cell Therapy Improves Damaged Heart In Study

Verastem Congratulates Co-founder Robert Weinberg and Announces the Presentation of Data at the 2012 AACR Annual Meeting

Posted: March 27, 2012 at 1:06 pm

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Verastem, Inc., (NASDAQ: VSTM - News) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells (CSCs), congratulates Robert Weinberg, Ph.D., Verastem co-founder and co-chair of the Scientific Advisory Board, and announces the presentation of preclinical data at the American Association for Cancer Research annual meeting being held March 31 to April 4, 2012, in Chicago, IL.

Dr. Weinberg has been awarded the 2012 Pezcoller Foundation-AACR International Award for Cancer Research for his outstanding work in the fields of cancer genetics and cell biology. Dr. Weinberg will deliver an award lecture entitled Epithelial-Mesenchymal Transition, Cancer Stem Cells and Metastasis at the annual meeting on Monday, April 2, 2012.

Verastem will present data on its programs targeting the focal adhesion kinase (FAK; VS-4718 and VS-5095) and Wnt/Beta-catenin (VS-507) signaling pathways. Research on the FAK and Wnt/Beta-catenin signaling pathways has revealed critical roles for each in the survival and metastatic capability of CSCs. Verastem will present data on FAK and Wnt inhibition in preclinical cancer models as well as data on the development of biomarkers for companion diagnostic tests to identify CSCs.

The schedule for Dr. Weinbergs award address and Verastems poster presentations is as follows:

Dr. Weinbergs award lecture: Date & Time: Monday, April 2, 2012, at 5:30 p.m. (CT) Title: Epithelial-Mesenchymal Transition, Cancer Stem Cells and Metastasis Location: Skyline Ballroom of McCormick Place

Verastems poster presentations: Date & Time: Monday, April 2, 2012, from 1:00 to 5:00 p.m. (CT) Poster Title: The FAK Inhibitors VS-4718 and VS-5095 Attenuate Breast Cancer Stem Cell Function In Vitro and Tumor Growth In Vivo Abstract Number: LB-192 Location: McCormick Place West (Hall F), Poster Section 38

Date & Time: Monday, April 2, 2012, from 1:00 to 5:00 p.m. (CT) Poster Title: The Wnt Inhibitor VS-507 Reduces Cancer Stem Cell Function In Vitro and Tumorigenicity in Mice Abstract Number: LB-194 Location: McCormick Place West (Hall F), Poster Section 38

Date & Time: Monday, April 2, 2012, from 1:00 to 5:00 p.m. (CT) Poster Title: An Alternative Splicing Signature that Identifies Breast Cancer Stem Cells Abstract Number: LB-197 Location: McCormick Place West (Hall F), Poster Section 38

About Verastem, Inc.

See the rest here:
Verastem Congratulates Co-founder Robert Weinberg and Announces the Presentation of Data at the 2012 AACR Annual Meeting

Posted in Stem Cells | Comments Off on Verastem Congratulates Co-founder Robert Weinberg and Announces the Presentation of Data at the 2012 AACR Annual Meeting

Genetic Risk and Stressful Early Infancy Join to Increase Risk for Schizophrenia

Posted: March 27, 2012 at 1:05 pm

- Human genome and mouse studies identify new precise genetic links

Newswise Working with genetically engineered mice and the genomes of thousands of people with schizophrenia, researchers at Johns Hopkins say they now better understand how both nature and nurture can affect ones risks for schizophrenia and abnormal brain development in general.

The researchers reported in the March 2 issue of Cell that defects in a schizophrenia-risk genes and environmental stress right after birth together can lead to abnormal brain development and raise the likelihood of developing schizophrenia by nearly one and half times.

Our study suggests that if people have a single genetic risk factor alone or a traumatic environment in very early childhood alone, they may not develop mental disorders like schizophrenia, says Guo-li Ming, M.D., Ph.D., professor of neurology and member of the Institute for Cell Engineering at the Johns Hopkins University School of Medicine. But the findings also suggest that someone who carries the genetic risk factor and experiences certain kinds of stress early in life may be more likely to develop the disease.

Pinpointing the cause or causes of schizophrenia has been notoriously difficult, owing to the likely interplay of multiple genes and environmental triggers, Ming says. Searching for clues at the molecular level, the Johns Hopkins team focused on the interaction of two factors long implicated in the disease: Disrupted-in-Schizophrenia 1 (DISC1) protein, which is important for brain development, and GABA, a brain chemical needed for normal brain function.

To find how these factors impact brain development and disease susceptibility, the researchers first engineered mice to have reduced levels of DISC1 protein in one type of neuron in the hippocampus, a region of the brain involved in learning, memory and mood regulation. Through a microscope, they saw that newborn mouse brain cells with reduced levels of DISC1 protein had similar sized and shaped neurons as those from mice with normal levels of DISC1 protein. To change the function of the chemical messenger GABA, the researchers engineered the same neurons in mice to have more effective GABA. Those brain cells looked much different than normal neurons, with longer appendages or projections. Newborn mice engineered with both the more effective GABA and reduced levels of DISC1 showed the longest projections, suggesting, Ming said, that defects in both DISC1 and GABA together could change the physiology of developing neurons for the worse.

Meanwhile, other researchers at University of Calgary and at the National Institute of Physiological Sciences in Japan had shown in newborn mice that changes in environment and routine stress can impede GABA from working properly during development. In the next set of experiments, the investigators paired reducing DISC1 levels and stress in mice to see if it could also lead to developmental defects. To stress the mice, the team separated newborns from their mothers for three hours a day for ten days, then examined neurons from the stressed newborns and saw no differences in their size, shape and organization compared with unstressed mice. But when they similarly stressed newborn mice with reduced DISC1 levels, the neurons they saw were larger, more disorganized and had more projections than the unstressed mouse neurons. The projections, in fact, went to the wrong places in the brain.

Next, to see if their results in mice correlated to suspected human schizophrenia risk factors, the researchers compared the genetic sequences of 2,961 schizophrenia patients and healthy people from Scotland, Germany and the United States. Specifically, they determined if specific variations of DNA letters found in two genes, DISC1 and a gene for another protein, NKCC1, which controls the effect of GABA, were more likely to be found in schizophrenia patients than in healthy individuals. They paired 36 DNA letter changes in DISC1 and two DNA letter variations in NKCC1 one DNA letter change per gene in all possible combinations. Results showed that if a persons genome contained one specific combination of single DNA letter changes, then that person is 1.4 times more likely than people without these DNA changes to develop schizophrenia. Having these single DNA letter changes in either one of these genes alone did not increase risk.

Now that we have identified the precise genetic risks, we can rationally search for drugs that correct these defects, says Hongjun Song, Ph.D., co-author, professor of neurology and director of the Stem Cell Program at the Institute for Cell Engineering.

Other authors of the paper from Johns Hopkins are Ju Young Kim, Cindy Y. Liu, Fengyu Zhang, Xin Duan, Zhexing Wen, Juan Song, Kimberly Christian and Daniel R. Weinberger. Emer Feighery, Bai Lu and Joseph H. Callicott from the National Institute of Mental Health, Dan Rujescu of Ludwig-Maximilians-University, and David St Clair of the University of Aberdeen Royal Cornhill Hospital are additional authors.

See more here:
Genetic Risk and Stressful Early Infancy Join to Increase Risk for Schizophrenia

Posted in Genetic Engineering | Comments Off on Genetic Risk and Stressful Early Infancy Join to Increase Risk for Schizophrenia

Midlands Vet Uses Stem Cell Therapy for Pets in Pain

Posted: March 27, 2012 at 1:04 pm

Columbia, SC (WLTX) --What if your pet couldn't walk anymore? One Midlands vet is using stem cell therapy to help.

For Beth Phibbs it's almost like a turning back of the hands of time.

"I call her my little miracle dog, because she's doing things she used to do," said Phibbs. "Now she's not on any medication, and she can go up and down the steps and she runs and jumps and things that she used to do when she was five."

Phibbs has spent the last 13 years loving and looking after her pet dog Maggie, and when she pet began to develop arthritis and a limp she had to take action. But when the first treatments stopped working, Phibbs and Maggie had to look to another options, dog stem cell therapy.

"I had no idea that animals were able to have they type of procedures," she said.

Dr. Kenneth Banks a veterinarian with the Bank Animal Hospital, performed the surgery for Maggie using her own stem cells in the one day procedure.

Banks said the stem cell therapy not only cost less than some other options, but was less invasive and had a quicker recovery time as well.

Still with about three similar procedures under his belt, even he didn't expect to see a such change in maggie just 40 days after the surgery.

"I wasn't sure we were gonna get the results this fast, we were expecting results, maybe not a good as she's done. We're real happy with her results," said Banks.

Now, after three years on medication and walking with a limp, Maggie's getting used to a new way of life -- one with out pain in her golden years.

Read the original post:
Midlands Vet Uses Stem Cell Therapy for Pets in Pain

Posted in Cell Therapy | Comments Off on Midlands Vet Uses Stem Cell Therapy for Pets in Pain

Page 2,803«..1020..2,8022,8032,8042,805..2,8102,820..»